FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Published:2021-08-20 Issue:3 Volume:28 Page:441-445
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Chang Elaine^ORCID,Weinstock Chana,Zhang Lijun,Fiero Mallorie H.,Zhao Miao,Zahalka Eias,Ricks Tiffany K.,Fourie Zirkelbach Jeanne,Qiu Junshan,Yu Jingyu,Chen Xiao Hong^ORCID,Bhatnagar Vishal,Goldberg Kirsten B.^ORCID,Tang Shenghui,Kluetz Paul G.,Pazdur Richard,Ibrahim Amna^ORCID,Beaver Julia A.,Amiri-Kordestani Laleh

Funder

HHS | U.S. Food and Drug Administration

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I Study of Tivozanib Eye Drops in Healthy Volunteers and Patients with Neovascular Age-Related Macular Degeneration;Ophthalmology Science;2024-11

2. Targeted nanomedicine modulating intercellular communications to arrest renal cell carcinoma progression;Journal of Drug Delivery Science and Technology;2024-09

3. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment;Microvascular Research;2024-07

4. Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties;Bioorganic Chemistry;2024-06

5. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas;Pharmacological Research;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP